<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552705</url>
  </required_header>
  <id_info>
    <org_study_id>46092</org_study_id>
    <secondary_id>CDMRP-PR171647</secondary_id>
    <nct_id>NCT03552705</nct_id>
  </id_info>
  <brief_title>The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients</brief_title>
  <official_title>Novel Strategies to Combat Post-Traumatic Osteoarthritis (PTOA):The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who tear their ACL are at high risk for developing arthritis (post-traumatic
      osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to
      deterioration of joint health. This study will determine whether treatment with Tranexamic
      Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and
      reconstructive surgery reduces inflammation and improves joint health as a new strategy to
      prevent or delay the onset of PTOA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded RCT</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Synovial fluid IL-1</measure>
    <time_frame>Day 5</time_frame>
    <description>To determine whether TXA administered acutely after ACL injury reduces synovial fluid markers of inflammation and cartilage degradation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Reported Outcomes (PRO): Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>6 months post-ACLR</time_frame>
    <description>To determine whether TXA administered acutely after ACL injury and during ACLR surgery improves PRO (KOOS Quality of Life) at 6 months after ACLR. The Knee injury and Osteoarthritis Outcome Score (KOOS) assesses a patient's opinion about their knee and associated problems. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative MRI (qMRI)</measure>
    <time_frame>6 months post-ACLR</time_frame>
    <description>To determine whether TXA administered acutely after ACL injury and during ACLR surgery improves cartilage subsurface matrix structure assessed by qMRI UTE-T2* at 6 months after ACLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative MRI</measure>
    <time_frame>2 years post-ACLR</time_frame>
    <description>To determine whether TXA administered acutely after ACL injury and during ACLR surgery improves cartilage subsurface matrix structure assessed by qMRI UTE-T2* at 2 years after ACLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes (PRO): Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>2 years post-ACLR</time_frame>
    <description>To determine whether TXA administered acutely after ACL injury and during ACLR surgery improves PRO (KOOS Quality of Life) at 2 years after ACLR. The Knee injury and Osteoarthritis Outcome Score (KOOS) assesses a patient's opinion about their knee and associated problems. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Anterior Cruciate Ligament Reconstruction</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5-day course of placebo and intravenous saline during ACL reconstruction surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>5-day course of oral placebo and intravenous saline during ACL reconstruction surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-30 years

          -  within 4 days of unilateral ACL injury

          -  presence of effusion/hemarthrosis.

        Exclusion Criteria:

          -  inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/
             pseudogout

          -  systemic or acute illness requiring medications

          -  concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery

          -  prior surgery to either knee

          -  prior injury to either knee requiring crutches

          -  history of thromboembolic disease

          -  current use of combination hormonal contraception

          -  chronic NSAID use

          -  cortisone injection to either knee within the prior 3 months

          -  not indicated for or unable to undergo ACLR within 3 months of injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constance Chu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hledik, PhD</last_name>
    <phone>650-721-7612</phone>
    <email>jerhart@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hoang</last_name>
      <phone>650-721-7612</phone>
      <email>c1hoang@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brittney Deadwiler</last_name>
      <phone>650-721-7612</phone>
      <email>brittcd@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Constance R. Chu, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

